The FDA-approved Inluriyo, an oral estrogen receptor antagonist from Eli Lilly, has shown to achieve significant improvement in progression-free survival for breast cancer.
Original Source:
https://www.foxnews.com/health/new-breast-cancer-drug-wins-fda-approval-slashing-progression-risk-nearly-40
